title: [Prophylactic effect of UFT in combination with intravesical chemotherapy on the recurrence of superficial bladder tumor].
abstract: The influence of N1-(2-tetrahydrofuryl)-5-fluorouracil plus uracil (UFT) on the recurrence of superficial bladder tumors was evaluated in a randomized clinical study. Group A (n = 196) underwent transurethral resection (TUR) and the intravesical chemoprophylaxis, while group B (n = 193) received 400 mg per a day of UFT orally for 6 months in addition to the instillation therapy. These adjuvant therapy was started one week after TUR. Consequently, 30 patients in group B showed UFT-related toxicity and administration of UFT was discontinued in 10 of them. In addition, 87 patients in group B did not complete the 6-month course of UFT administration. Comparison of 2-year actuarial non-recurrence curves revealed no significant difference between groups A and B. However, UFT seemed to have a favorable prophylactic effect when recurrence rates were compared among those patients with recurrent tumors (generalized Wilcoxon: p = 0.1277), and those with recurrent multiple tumors (p = 0.0847).
authors.affiliation: Department of Urology, Kyoto University Faculty of Medicine.
authors.forename: O
authors.initials: O
authors.lastname: Yoshida
authors.forename: Y
authors.initials: Y
authors.lastname: Kakehi
authors.forename: Y
authors.initials: Y
authors.lastname: Nishio
authors.forename: T
authors.initials: T
authors.lastname: Tomoyoshi
authors.forename: T
authors.initials: T
authors.lastname: Konami
authors.forename: T
authors.initials: T
authors.lastname: Usui
authors.forename: M
authors.initials: M
authors.lastname: Igawa
authors.forename: I
authors.initials: I
authors.lastname: Takenaka
authors.forename: K
authors.initials: K
authors.lastname: Fujita
mesh_terms: D000283:Administration, Intravesical; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D015653:Cystectomy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011292:Premedication; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
chemical_list: D005641:Tegafur; D016685:Mitomycin; D014498:Uracil; D004317:Doxorubicin